Navigation Links
Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2014 And Announces ARRY-520 Development Strategy
Date:10/31/2013

ative to the previously-evaluated formulation. In addition, the study is evaluating safety and the preliminary efficacy of ARRY-614 based on Hematologic Improvement (increases in red blood cells, neutrophils and/or platelets), the reduction or independence from red blood cell and/or platelet transfusions, the durability of these responses, and OS.  Mature response data from this trial is expected early next year.  With these results, Array plans to discuss development plans with regulatory authorities.An abstract providing updated data on the current ARRY-614 study has been submitted for presentation at the 2013 ASH Annual Meeting.

Partnered Pipeline ProductsMEK162 (co-developing with Novartis) – Phase 3 trial initiated in BRAF-mutant melanoma
Novartis initiated a Phase 3 trial with MEK162 and the Novartis BRAF inhibitor, LGX818, in BRAF-mutant melanoma based on the safety and efficacy data reported in their trial presented at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting.  The trial, called COLUMBUS, is a 900-patient randomized, open label, multi-center, parallel group, three-arm study comparing the efficacy and safety of LGX818 plus MEK162 and LGX818 monotherapy, as compared to vemurafenib in patients with locally advanced unresectable or metastatic melanoma with BRAF mutation.

There are now three Phase 3 trials enrolling with MEK162 in advanced cancer patients:  NRAS-mutant melanoma, low-grade serous ovarian cancer and BRAF-mutant melanoma.  NRAS-mutant melanoma represents the first indication for MEK162, and the projected regulatory filing from the NRAS-mutant melanoma study is estimated to be in 2015.Selumetinib (partnered with AstraZeneca) – SELECT-1 Phase 3 trial initiated in non-small cell lung cancer (NSCLC)
AstraZeneca initiated a Phase 3 clinical trial of selumetinib as second-line therapy in patients with KRAS-mutant advanced or metastatic NSCLC based on the strength of Phas
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
2. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
3. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
4. Array BioPharma Announces Proposed Public Offering Of Common Stock
5. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
6. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
7. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
10. Array BioPharma To Present At The Cowen Annual Health Care Conference
11. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... CAMBRIDGE, Mass. , Aug. 3, 2015 ... the company will host its Second Quarter 2015 Investor ... August 10.    The call will cover ... summary of second quarter 2015 financials. A press release ... will be issued the afternoon of Monday, August 10. ...
(Date:8/3/2015)... SAN FRANCISCO, Calif. , Aug. 3, 2015 ... for the treatment of cancer, today announced the ... Debanjan Ray , who previously ... alliance management, has been promoted to senior vice ... joining CytomX, Mr. Ray held positions as the ...
(Date:8/3/2015)... 3, 2015  Celsion Corporation (NASDAQ: CLSN ... a conference call to discuss its second quarter ... its development programs for ThermoDox®, its proprietary heat-activated ... technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy and ... August 10, 2015. To participate in the call, ...
Breaking Medicine Technology:Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... New England Journal of Medicine employs Quest Diagnostics, blood-based ... of blood specimens may detect abnormal white blood cells ... leukemia (CLL) develops, according to research published in the ... Journal of Medicine . The finding may lead to ...
... Pharmacyclics (Nasdaq: PCYC ) announced today ... investment by the principals of Pacific Biopharma Group, Ltd. ... Province, People,s Republic of China. The transaction was structured ... Pharmacyclics at $0.93/share. Robert Duggan, CEO of Pharmacyclics ...
Cached Medicine Technology:Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 2Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 3Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 4Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd. 2Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd. 3
(Date:8/3/2015)... ... August 03, 2015 , ... As reported in a ... series, “Atlanta Plastic” is getting attention for moving outside traditional ethnic stereotypes when ... African-American cast of doctors and patients. Beverly Hills based plastic surgeon Payam Jarrah-Nejad, ...
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today ... B2B Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, ... for the launch of their Readmissions Analytics product was selected as one of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
(Date:8/3/2015)... ... August 03, 2015 , ... The art of preparing and ... her grandmother’s side at a young age, Nasreen Zereshki was extremely eager to cook ... share her cookbook Recipes from My Persian Kitchen with the world. , Since Americans ...
(Date:8/3/2015)... ... 2015 , ... The U.S. Food and Drug Administration (FDA) recently approved a ... acid, which occurs naturally in the body and helps absorb and breakdown fat cells. ... the body. These are invasive procedures and very expensive for most people. Now with ...
Breaking Medicine News(10 mins):Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3
... Ex-police officer and certified search & rescue manager won contest to ... , LOS ANGELES, June 17 Can ... of the late search and rescue dog and 9-11 hero, Trakr, ... 2009. BioArts International, a Northern California biotech company that is offering ...
... ... ... -- The IMTA and PATA recently signed a Memorandum of Understanding (MOU) to promote healthcare ... development of this high value sector and drive more integration between the travel and healthcare ...
... ... practice to a brand new state of the art location at 5044 Tennyson in Plano. ... Laser Surgery. , ... 2009 -- Dr. Bryan Selkin, the Chief Dermatologist of the Dermatology Center of Plano will be ...
... Two Cold Remedy Nasal Products Citing Commitment to Consumer Safety ... Matrixx Initiatives, Inc. (Nasdaq: MTXX ) has confirmed ... Food and Drug Administration about two of its 19 existing ... Cold Remedy Swabs. The warning letter cited consumer reports that ...
... June 16 Mammography has long been the standard for ... tissue can make tumors difficult to find. According to ... tissue are five times more likely to develop breast cancer. ... SI ) at: http://inr.mediaseed.tv/oneClip_C/?feed=KmAdskkAWyriUTQcX9fLjuG_zA0wEhsO ...
... PHILADELPHIA, June 16 United States Attorney Michael L. ... today announced the return of an indictment(1.) against Norian ... executives, Michael D. Huggins (Huggins), Thomas B. Higgins (Higgins), ... charging them for their involvement in conducting clinical trials ...
Cached Medicine News:Health News:BioArts International Clones 9-11 Hero Dog - Owner to Receive Five Cloned Puppies June 17 in Los Angeles 2Health News:BioArts International Clones 9-11 Hero Dog - Owner to Receive Five Cloned Puppies June 17 in Los Angeles 3Health News:The International Medical Travel Association (IMTA) and Pacific Asia Travel Association (PATA) sign MOU to Promote Healthcare Travel 2Health News:The International Medical Travel Association (IMTA) and Pacific Asia Travel Association (PATA) sign MOU to Promote Healthcare Travel 3Health News:New State of the Art Dermatology Center in Plano TX 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 3Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 2Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 3Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 4Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 5Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 6Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 7
... has greatly enhanced the stabilization ... Biomet Low Profile Tibial Nail ... treatment of unstable fractures, tibial ... pathologic or impending fractures but ...
Arthroscopic instrument system for instability and SLAP fixation....
Arthroscopic instrument system for instability and SLAP fixation....
Suture Cutter, Open Ended, Left Notch...
Medicine Products: